GlaxoSmithKline Pharmaceuticals Limited (GLAXO) AI Stock Analysis

• Market Cap: ₹474.25B
• Dividend Yield: 1.93%
• Average Volume (3M): 3.95K
• Price to Earnings (P/E): 49.9
• Beta (1Y): 0.85
• Revenue Growth: 6.65%
• EPS Growth: 48.47%
• Country: IN
• Employees: 3,211
• Sector: Healthcare
• Sector Strength: 47
• Industry: Drug Manufacturers - General
• EPS (TTM): 12.10
• Shares Outstanding: 169,406,040
• 10 Day Avg. Volume: 5,563
• 30 Day Avg. Volume: 3,947
• PEG Ratio: 0.89
• Price to Book (P/B): 24.28
• Price to Sales (P/S): 12.64
• P/FCF Ratio: 37.40
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹3,160.00
• Price Target Upside: 12.88% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 65 Neutral
• Price Target: ₹3,160.00 ▲(12.88% Upside)

GlaxoSmithKline Pharmaceuticals Limited shows strong financial performance with robust profitability and efficient cash management. However, technical analysis indicates bearish momentum, and the high P/E ratio suggests potential overvaluation. These factors contribute to a moderate overall stock score.

GlaxoSmithKline Pharmaceuticals Limited Business Overview & Revenue Model

Company Description

GlaxoSmithKline Pharmaceuticals Limited (GLAXO) is a leading global healthcare company engaged in the research, development, and manufacturing of pharmaceutical products, vaccines, and consumer healthcare goods. With a focus on innovation, GLAXO operates in various sectors including pharmaceuticals, vaccines, and consumer healthcare, delivering solutions in areas such as respiratory, oncology, and HIV, among others.

How the Company Makes Money

GlaxoSmithKline Pharmaceuticals Limited generates revenue primarily through the research, development, and sale of pharmaceutical products and vaccines. The company earns money by developing patented medicines that treat a range of conditions, such as respiratory diseases, cancer, and infectious diseases like HIV. It also makes money from its vaccines division by producing and distributing vaccines for diseases such as influenza, shingles, and meningitis. The consumer healthcare division contributes to revenue through the sale of non-prescription products including oral health, pain relief, and wellness supplements. The company leverages strategic partnerships and collaborations with other pharmaceutical companies and research institutions to enhance its product offerings and extend its market reach. Additionally, GLAXO's earnings are influenced by regulatory approvals, patent protections, and global healthcare spending trends.

GlaxoSmithKline Pharmaceuticals Limited Financial Statement Overview

Summary

GlaxoSmithKline Pharmaceuticals Limited exhibits a strong financial profile with impressive revenue growth, robust profitability, and efficient cash flow management. The company maintains a solid balance sheet with low leverage and high liquidity, positioning it well for future opportunities and challenges in the pharmaceutical industry.

Income Statement

GlaxoSmithKline Pharmaceuticals Limited shows strong financial performance with a consistent increase in total revenue over the years. For the latest fiscal year, the company achieved a Gross Profit Margin of 62.88% and a Net Profit Margin of 24.74%, indicating healthy profitability. The Revenue Growth Rate was 8.92%, showcasing robust top-line growth. Additionally, the company reported a solid EBIT Margin of 47.45% and an EBITDA Margin of 31.40%, reflecting efficient operational management.

Balance Sheet

The balance sheet demonstrates a strong financial position with a low Debt-to-Equity Ratio of 0.005, suggesting minimal financial leverage. The Return on Equity (ROE) stands at 47.53%, indicating efficient use of equity to generate profits. The Equity Ratio of 47.50% highlights a balanced capital structure. The company maintains substantial liquidity, evidenced by significant cash reserves.

Cash Flow

The cash flow analysis reveals positive trends with a substantial Free Cash Flow Growth Rate of 129.96% in the latest fiscal year. The Operating Cash Flow to Net Income Ratio is 1.39, suggesting strong cash generation relative to net income. Additionally, the Free Cash Flow to Net Income Ratio is 1.37, reflecting robust cash flow management and the ability to support ongoing operations and investments.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	37.49B	37.49B	34.42B	32.52B	32.78B	31.99B
Gross Profit	20.23B	23.58B	20.22B	19.67B	18.28B	18.04B
EBITDA	12.54B	11.77B	8.87B	9.03B	8.49B	5.36B
Net Income	9.28B	9.28B	5.90B	6.11B	3.81B	3.58B
Balance Sheet
Total Assets	41.08B	41.08B	35.57B	33.27B	46.33B	31.13B
Cash, Cash Equivalents and Short-Term Investments	25.22B	25.22B	18.57B	18.12B	29.03B	11.37B
Total Debt	99.50M	99.50M	186.65M	155.40M	200.76M	346.27M
Total Liabilities	21.57B	21.57B	17.79B	15.85B	19.70B	16.14B
Stockholders Equity	19.51B	19.51B	17.78B	17.41B	26.63B	14.99B
Cash Flow
Free Cash Flow	0.00	12.67B	5.51B	4.40B	7.76B	5.34B
Operating Cash Flow	0.00	12.90B	5.82B	4.84B	8.11B	5.78B
Investing Cash Flow	0.00	-458.10M	-847.21M	8.08B	-4.06B	4.19B
Financing Cash Flow	0.00	-7.69B	-5.61B	-15.43B	-5.24B	-6.96B

GlaxoSmithKline Pharmaceuticals Limited Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 2799.50
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:GLAXO, the sentiment is Neutral. The current price of 2799.5 is below the 20-day moving average (MA) of 2860.56, below the 50-day MA of 3091.06, and above the 200-day MA of 2678.40, indicating a neutral trend. The MACD of -96.24 indicates Negative momentum. The RSI at 41.70 is Neutral, neither overbought nor oversold. The STOCH value of 76.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:GLAXO.

GlaxoSmithKline Pharmaceuticals Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LUPIN	75 Outperform	₹902.33B	24.37		0.61%	12.40%	63.16%
DRREDDY	74 Outperform	₹1.07T	18.75		0.62%	15.86%	2.02%
CIPLA	73 Outperform	₹1.29T	23.85		0.82%	6.40%	25.27%
SUNPHARMA	73 Outperform	₹3.94T	38.00		0.97%	9.28%	-0.17%
TORNTPHARM	73 Outperform	₹1.25T	62.29		0.87%	7.63%	15.39%
GLAXO	65 Neutral	₹474.25B	49.91		1.93%	6.65%	48.47%
Sector *	51 Neutral	$7.89B	-0.12	-39.89%	2.16%	21.38%	-1.56%

GlaxoSmithKline Pharmaceuticals Limited Corporate Events

GlaxoSmithKline Pharmaceuticals Enhances Investor Communication

GlaxoSmithKline Pharmaceuticals Limited has announced the presentation of its Analyst/Institutional Investor Meetings, which will be accessible on their website. This move aligns with regulatory requirements and aims to enhance transparency and communication with stakeholders, potentially impacting investor relations and market perception.